4-MMC (4-methylmethcathinone), more commonly known as mephedrone, is a synthetic psychostimulant and entactogen of the substituted cathinone class. It shares a structural kinship with both amphetamine (as a beta-keto analogue) and the natural cathinone alkaloids found in the khat plant (Catha edulis), native to East Africa. First synthesised in 1929 and largely forgotten, it was rediscovered in 2003 by an underground chemist and commercialised shortly after, reaching mass popularity by 2007–2010. Mephedrone is typically encountered as a fine white, off-white, or yellowish powder with a distinctive chemical odour; it is soluble in water and usually consumed by insufflation (snorting), oral ingestion (in gel capsules or "bombs" of folded paper), or less commonly by intravenous injection.
Pharmacologically, 4-MMC occupies an unusual and compelling position — it is simultaneously a potent monoamine releaser and reuptake inhibitor acting across all three major catecholamine systems: dopamine (DA), serotonin (5-HT), and norepinephrine (NE). This triple-action profile places it between cocaine/amphetamine on the stimulant axis and MDMA on the entactogenic axis, producing a subjective experience that users commonly describe as a hybrid: the drive and euphoria of cocaine, the sociability and emotional openness of MDMA, with a notably shorter duration than either. The drug's serotonergic potency gives it genuine empathogenic character, while its robust dopaminergic release accounts for its high compulsive redosing liability — arguably its most dangerous property.
Mephedrone first achieved popularity in Israel around 2007, where it was sold legally under names like "hagigat." It rapidly spread to the United Kingdom, where it was sold openly as "plant food" and labelled "not for human consumption" to exploit a legal loophole. By 2009 it had become one of the most widely used recreational drugs in British nightlife, particularly in club and festival contexts. British tabloid media adopted the nickname "meow meow" and ran extensive — often factually inaccurate — coverage linking the drug to deaths, which paradoxically amplified its popularity. On 16 April 2010, mephedrone was classified as a Class B controlled substance in the UK under the Misuse of Drugs Act 1971, in what was the world's first generic legislative ban targeting an entire class of cathinones by chemical structure.
The community experience of mephedrone is defined by two competing realities. On the positive side, users describe a rush of euphoria and confidence, enhanced sociability and tactile sensation, increased libido (more reliably than MDMA), and a musicality enhancement that rivals traditional entactogens. On the negative side, the brevity of each "peak" — roughly 45–90 minutes per dose — creates intense pressure to redose, and sessions routinely escalate into multi-hour or multi-day binges that users describe as almost impossible to voluntarily stop. This compulsive use pattern, driven by the drug's dopaminergic mechanism, distinguishes 4-MMC from MDMA and places it closer to cocaine in terms of addiction liability.
Legally, mephedrone is now a controlled substance in the overwhelming majority of jurisdictions globally: Class B in the United Kingdom (2010), Schedule I in the United States (2011, made permanent 2012), and prohibited across the European Union following a December 2010 EU Council decision. It continues to circulate on illicit markets and remains one of the most studied and discussed synthetic cathinones in the scientific and harm reduction literature.